Isoprinosine was used under doubleblind, randomised, and placebocontrolled conditions in 52 patients with relapsinglremitting or progressive multiple sclerosis. All patients received pulsed treatment with methylprednisolone. There was no significant effect of treatment on clinical disability or the accumulation of MRI abnormalities, after correction of results for multiple comparisons. It is concluded that isoprinosine is not effective therapy for multiple sclerosis.
Despite steady progress in understanding the pathogenesis of multiple sclerosis, treatment that influences the long-term course of the disease has yet to be identified. Pulsed, highdose, intravenous methylprednisolone is now used widely in the management of acute relapse and also improves disability arising from spasticity in some patients with chronic progressive disease.' 2 The consensus view on the use of currently available immunosuppressive treatments is that these are not effective or, at best, stabilise the rate of accumulation of disability after a delay of many months. Statistically significant results have been reported after long-term treatment but the therapeutic benefits are rarely useful for the individual patient. Most of these treatments carry significant adverse effects.
In the study reported here and in previous trials,'3 the use of pulsed, intravenous methylprednisolone was followed by long-term oral immunological therapy in an attempt to achieve rapid and sustained clinical improvements. Isoprinosine was selected for oral therapy because, during the design phase, this was considered to be effective in several tissue specific disorders characterised by an inappropriate immune response. Isoprinosine is remarkably free from adverse effects45 and preliminary evidence suggested a beneficial role in the treatment of multiple sclerosis.s9
Intravenous methylprednisolone was given electively to all patients at the start of the study. Participants were then randomised to receive oral isoprinosine under double-blind and placebo-controlled conditions. Clinical outcome measures (relapse frequency, expanded disability status, and ambulation index) were supplemented by quantitative MRI. This preliminary study was limited to about 50 participants, given the relative lack of clinical information relating to the use of isoprinosine in multiple sclerosis.
Materials and methods

PATIENTS
A population-based register of patients with multiple sclerosis was used to identify patients suitable for inclusion in the study. A total of 104 patients, with scores on 1 January 1986 of <5-5 on the Kurtzke expanded disability status scale (EDSS)10 were invited to discuss participation in the trial. Each patient had been classified with the Poser criteriall and had clinically definite or laboratory supported probable disease. Eighty-three were later interviewed and examined. Twentyeight were not willing to take part or were considered unsuitable because at review the clinical manifestations were negligible or had become too severe for inclusion in the study. Despite this precaution, a number of recruited patients subsequently deteriorated and had a Kurtzke EDSS of >5 5 at the time of entry. The trial protocol was described verbally and in writing to each participant who signed a statement of consent. Fifty-four patients entered the study but two were subsequently withdrawn because of failure to follow the agreed protocol. Three others completed most of the trial but were lost to follow up at two years. One discontinued treatment because of pregnancy. 
METHODS
STATISTICS
Mean age and baseline disability scores were compared by t tests. The distributions for duration of disease and ambulation index were skewed and are therefore described as medians, which were compared with the nonparametric Mann-Whimey test. This test was also used to compare median numbers of new or enlarged and disappeared or decreased lesions demonstrated by MRI. The results of treatment were compared between groups by analysis of covariance with disability score at each follow-up point as outcome and baseline assessment as covariate. Tests of significance were corrected for multiple comparisons.
Results
CHARACTERISTICS AT ENTRY
Fifty-two patients completed the study; two patients withdrew before starting oral treatment with isoprinosine or placebo and were not included in the analysis. One patient stopped oral therapy after becoming pregnant, but her assessments continued for two years. Two patients were lost to follow up during the study. These three cases have been included in the analysis of results. Twenty five patients were randomised to active treatment with isoprinosine and 27 received placebo preparations. There were no significant differences between these groups in age, duration of disease, Kurtzke EDSS, or ambulation index at entry (table 1 ). An equal number of relapsing/remitting (26) and chronic progressive (26; four primary and 22 secondary progressive) cases were studied but, due to a randomisation error, more patients in the isoprinosine-treated (17/25) than placebo (9/27) group had relapsing/ remitting disease. Conversely, there was an excess of cases treated with placebo (18/26) compared with those treated with isoprinosine (8/26) in the chronic progressive group. Mean age was significantly higher in the isoprinosine-treated cases with relapsing/ remitting disease but, in all other respects, there were no baseline differences between patients actively treated or given placebo. The relapsing and chronic progressive patients were comparable with respect to age and duration of illness. It followed that, as a group, the chronic progressive cases were more disabled than relapsing patients at entry.
DISABILITY
Considering all subjects, there was no significant difference in disability scores between the treated and control groups at 16, 32, 64, 80, and 96 weeks. There was an effect in favour of isoprinosine treatment compared with the placebo group at 48 weeks (t = 2-08; p = 0 043; p, = 0 30). No significant differences in disability between patients treated with isoprinosine and placebo were seen when the subgroup of relapsing/remitting patients was separately analysed. There was a significant effect in favour of treatment with isoprinosine in chronic progressive cases at one week (t = 2-33; p < 0-029; Pc = 0 20) but not at any subsequent follow up point. Because of the non-random distribution of cases treated with isoprinosine and placebo with respect to clinical course, and the effect this had on baseline disability, the actively treated patients remained clinically less disabled throughout the period of follow up. As a group, their clinical course was stable until 48 weeks when there was a slight increase in disability. By contrast, the patients treated with placebo were consistently more disabled and had deteriorated considerably after 64 weeks.
The effects of active and placebo treatments were also compared in terms of the number of patients whose disability scores increased or decreased during the study. There was no significant difference between the two groups of relapsing/remitting patients but a greater proportion of placebo than actively treated progressive cases showed an increase in disability during the trial. This effect was also seen when the results were compared between all patients receiving isoprinosine and those receiving placebo, analysed without respect to clinical course. Taken with the analysis of covariance, this 
effect of treatment was not considered to be statistically significant.
AMBULATION INDEX
Changes in the ambulation index seemed to show a significant effect in favour of active treatment although this partly arose from the trend towards lower baseline ambulation indices in patients receiving isoprinosine. This effect was compounded by the randomisation error resulting in a significant difference in the number of relapsing/remitting and chronic progressive patients receiving active and placebo therapy. When median ambulation indices were compared separately in the relapsing/remitting and chronic progressive cases, there was no significant difference in either group at any follow-up point except for the relapsing/remitting patients at 16 weeks (p = 0-028; pc = 0d19). Active and placebo treatment has also been compared by identifying patients whose ambulation index increased or decreased during the study. There was a trend towards a more favourable course in all patients receiving isoprinosine, and in the sub-group of progressive cases, which was not seen in the relapsing/remitting group (table 2). Isoprinosine is a physicochemical complex of inosine with the para-acetamidobenzoic acid salt of N,N-dimethylamino-2-propanolol that enhances B lymphocyte activity, perhaps through an effect on T helper cells. It also increases macrophage phagocytosis, release of cytokines which induce macrophage proliferation including immune interferon and interleukins 1 and 2, and augments the action of T cell mitogens.45 1314 Modest success has been reported in diseases in which immune reactions are thought to complicate viral infection. There is a very low frequency of adverse effects attributable to treatment with isoprinosine. Neurological diseases that have been studied include subacute sclerosing panencephalitis,'5-18 progressive rubella encephalitis'9 and other encephalitides,20 amyotrophic lateral sclerosis,21 multiple sclerosis,6-9 and experimental allergic encephalomyelitis.22 Isoprinosine has been used in organ specific inflammatory diseases such as rheumatoid arthritis,2324 and in AIDS.25 26 Pompidou et al 7 compared the clinical and immunological effects of isoprinosine, chlorambucil, and a placebo preparation in a small cohort of patients with multiple sclerosis over 2 years. A higher dose of isoprinosine was used than in the present study and this makes it difficult to compare the results directly. Relapses occurred in each patient treated with chlorambucil or placebo preparations but in only a few patients receiving isoprinosine. These relapses did not differ in severity between the three groups but the authors reported a reduction in handicap associated with the use of isoprinosine. Immunological studies showed increased suppressor cell number and function in cases treated with isoprinosine, whereas cells with the T helper phenotype and delayed type hypersensitivity were reduced in patients receiving chlorambucil.
Multiple sclerosis has attracted many different approaches to treatment. In most studies, the effect of therapy has been so small as to require more participants than could easily be recruited by an individual investigator. This has led to the development of multicentre trials and meta-analyses,27-3" each of which combines strength in numbers with potential variations in methodology, selection of cases, and the application of research protocols. Perhaps the greatest barrier to progress has been extravagant reporting of results leading to a decline in the acceptability of placebo-controlled trials and the need for increasingly complex 
